• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
How to fix a broken protein: restoring function to mutant human cystathionine β-synthase.如何修复破损的蛋白质:恢复突变型人胱硫醚β-合酶的功能。
Hum Genet. 2022 Jul;141(7):1299-1308. doi: 10.1007/s00439-021-02386-w. Epub 2021 Oct 12.
2
Correction of cystathionine β-synthase deficiency in mice by treatment with proteasome inhibitors.通过使用蛋白酶体抑制剂纠正胱硫醚β-合酶缺乏症的小鼠模型。
Hum Mutat. 2013 Aug;34(8):1085-93. doi: 10.1002/humu.22335. Epub 2013 May 13.
3
Genetic and Pharmacological Modulation of Cellular Proteostasis Leads to Partial Functional Rescue of Homocystinuria-Causing Cystathionine-Beta Synthase Variants.遗传和药理学调节细胞蛋白稳态导致导致胱硫醚-β 合酶变异的高胱氨酸尿症的部分功能恢复。
Mol Cell Biol. 2023;43(12):664-674. doi: 10.1080/10985549.2023.2284147. Epub 2023 Dec 20.
4
Chaperone therapy for homocystinuria: the rescue of CBS mutations by heme arginate.同型胱氨酸尿症的伴侣蛋白疗法:血红素精氨酸对胱硫醚β-合酶突变的挽救作用
J Inherit Metab Dis. 2015 Mar;38(2):287-94. doi: 10.1007/s10545-014-9781-9. Epub 2014 Oct 21.
5
Potential Pharmacological Chaperones for Cystathionine Beta-Synthase-Deficient Homocystinuria.用于胱硫醚β-合酶缺乏型同型胱氨酸尿症的潜在药理伴侣分子。
Handb Exp Pharmacol. 2018;245:345-383. doi: 10.1007/164_2017_72.
6
Targeting Cystathionine Beta-Synthase Misfolding in Homocystinuria by Small Ligands: State of the Art and Future Directions.通过小分子配体靶向高胱氨酸尿症中的胱硫醚β-合酶错误折叠:现状与未来方向
Curr Drug Targets. 2016;17(13):1455-70. doi: 10.2174/1389450117666160302094910.
7
Mouse modeling and structural analysis of the p.G307S mutation in human cystathionine β-synthase () reveal effects on CBS activity but not stability.人胱硫醚-β-合酶()p.G307S 突变的小鼠建模和结构分析显示其对 CBS 活性有影响,但对稳定性无影响。
J Biol Chem. 2018 Sep 7;293(36):13921-13931. doi: 10.1074/jbc.RA118.002164. Epub 2018 Jul 20.
8
Recent therapeutic approaches to cystathionine beta-synthase-deficient homocystinuria.治疗胱硫醚β合酶缺乏型高胱氨酸尿症的新策略。
Br J Pharmacol. 2023 Feb;180(3):264-278. doi: 10.1111/bph.15991. Epub 2022 Dec 8.
9
Examination of two different proteasome inhibitors in reactivating mutant human cystathionine β-synthase in mice.检测两种不同的蛋白酶体抑制剂在小鼠中重新激活突变型人胱硫醚β-合酶的作用。
PLoS One. 2023 Jun 15;18(6):e0286550. doi: 10.1371/journal.pone.0286550. eCollection 2023.
10
Characterization of two pathogenic mutations in cystathionine beta-synthase: different intracellular locations for wild-type and mutant proteins.半胱氨酸β-合酶中两种致病突变的特征:野生型和突变型蛋白的不同细胞内位置。
Gene. 2013 Nov 15;531(1):117-24. doi: 10.1016/j.gene.2013.08.021. Epub 2013 Aug 24.

引用本文的文献

1
Deciphering pathophysiological mechanisms underlying cystathionine beta-synthase-deficient homocystinuria using targeted metabolomics, liver proteomics, sphingolipidomics and analysis of mitochondrial function.应用靶向代谢组学、肝蛋白质组学、鞘脂组学和线粒体功能分析破译胱硫醚β-合酶缺乏性高同型半胱氨酸尿症的病理生理机制。
Redox Biol. 2024 Jul;73:103222. doi: 10.1016/j.redox.2024.103222. Epub 2024 Jun 4.
2
Architecture and regulation of filamentous human cystathionine beta-synthase.丝氨酸-β-内酰胺酶的结构和调控
Nat Commun. 2024 Apr 4;15(1):2931. doi: 10.1038/s41467-024-46864-x.
3
Genetic and Pharmacological Modulation of Cellular Proteostasis Leads to Partial Functional Rescue of Homocystinuria-Causing Cystathionine-Beta Synthase Variants.遗传和药理学调节细胞蛋白稳态导致导致胱硫醚-β 合酶变异的高胱氨酸尿症的部分功能恢复。
Mol Cell Biol. 2023;43(12):664-674. doi: 10.1080/10985549.2023.2284147. Epub 2023 Dec 20.
4
Examination of two different proteasome inhibitors in reactivating mutant human cystathionine β-synthase in mice.检测两种不同的蛋白酶体抑制剂在小鼠中重新激活突变型人胱硫醚β-合酶的作用。
PLoS One. 2023 Jun 15;18(6):e0286550. doi: 10.1371/journal.pone.0286550. eCollection 2023.
5
HS biogenesis by cystathionine beta-synthase: mechanism of inhibition by aminooxyacetic acid and unexpected role of serine.半胱氨酸β-合酶介导的 HS 生物合成:氨基氧乙酸的抑制机制和丝氨酸的意外作用。
Cell Mol Life Sci. 2022 Jul 21;79(8):438. doi: 10.1007/s00018-022-04479-9.
6
Inherited metabolic disorders beyond the new generation sequencing era: the need for in-depth cellular and molecular phenotyping.新一代测序时代之后的遗传性代谢疾病:深入细胞和分子表型分析的必要性。
Hum Genet. 2022 Jul;141(7):1235-1237. doi: 10.1007/s00439-022-02467-4.

本文引用的文献

1
Homocystinuria patient and caregiver survey: experiences of diagnosis and patient satisfaction.同型胱氨酸尿症患者和照护者调查:诊断体验和患者满意度。
Orphanet J Rare Dis. 2021 Mar 10;16(1):124. doi: 10.1186/s13023-021-01764-x.
2
Classical homocystinuria: A common inborn error of metabolism? An epidemiological study based on genetic databases.经典同型胱氨酸尿症:一种常见的先天性代谢缺陷?一项基于遗传数据库的流行病学研究。
Mol Genet Genomic Med. 2020 Jun;8(6):e1214. doi: 10.1002/mgg3.1214. Epub 2020 Mar 30.
3
Proteostasis regulators modulate proteasomal activity and gene expression to attenuate multiple phenotypes in Fabry disease.蛋白稳态调节剂可调节蛋白酶体活性和基因表达,从而减轻法布里病的多种表型。
Biochem J. 2020 Jan 31;477(2):359-380. doi: 10.1042/BCJ20190513.
4
Analysis of the Qatari R336C cystathionine β-synthase protein in mice.分析卡塔尔 R336C 胱硫醚 β-合酶蛋白在小鼠中的作用。
J Inherit Metab Dis. 2019 Sep;42(5):831-838. doi: 10.1002/jimd.12140. Epub 2019 Jul 10.
5
Treatment of Cystathionine β-Synthase Deficiency in Mice Using a Minicircle-Based Naked DNA Vector.使用基于微环的裸 DNA 载体治疗胱硫醚 β-合酶缺乏症小鼠。
Hum Gene Ther. 2019 Sep;30(9):1093-1100. doi: 10.1089/hum.2019.014. Epub 2019 Jun 13.
6
Mouse modeling and structural analysis of the p.G307S mutation in human cystathionine β-synthase () reveal effects on CBS activity but not stability.人胱硫醚-β-合酶()p.G307S 突变的小鼠建模和结构分析显示其对 CBS 活性有影响,但对稳定性无影响。
J Biol Chem. 2018 Sep 7;293(36):13921-13931. doi: 10.1074/jbc.RA118.002164. Epub 2018 Jul 20.
7
Enzyme Replacement Therapy Ameliorates Multiple Symptoms of Murine Homocystinuria.酶替代疗法改善了小鼠同型胱氨酸尿症的多种症状。
Mol Ther. 2018 Mar 7;26(3):834-844. doi: 10.1016/j.ymthe.2017.12.014. Epub 2017 Dec 19.
8
Guidelines for the diagnosis and management of cystathionine beta-synthase deficiency.胱硫醚β-合酶缺乏症的诊断与管理指南。
J Inherit Metab Dis. 2017 Jan;40(1):49-74. doi: 10.1007/s10545-016-9979-0. Epub 2016 Oct 24.
9
Chaperone therapy for homocystinuria: the rescue of CBS mutations by heme arginate.同型胱氨酸尿症的伴侣蛋白疗法:血红素精氨酸对胱硫醚β-合酶突变的挽救作用
J Inherit Metab Dis. 2015 Mar;38(2):287-94. doi: 10.1007/s10545-014-9781-9. Epub 2014 Oct 21.
10
Structural insight into the molecular mechanism of allosteric activation of human cystathionine β-synthase by S-adenosylmethionine.S-腺苷甲硫氨酸对人胱硫醚β-合酶变构激活分子机制的结构洞察。
Proc Natl Acad Sci U S A. 2014 Sep 16;111(37):E3845-52. doi: 10.1073/pnas.1414545111. Epub 2014 Sep 2.

如何修复破损的蛋白质:恢复突变型人胱硫醚β-合酶的功能。

How to fix a broken protein: restoring function to mutant human cystathionine β-synthase.

机构信息

Cancer Signaling and Epigenetics Program, Fox Chase Cancer Center, Philadelphia, PA, USA.

出版信息

Hum Genet. 2022 Jul;141(7):1299-1308. doi: 10.1007/s00439-021-02386-w. Epub 2021 Oct 12.

DOI:10.1007/s00439-021-02386-w
PMID:34636997
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9003067/
Abstract

Inborn errors of metabolism (IEM) comprise a large class of recessive genetic diseases involving disorders of cellular metabolism that tend to be caused by missense mutations in which a single incorrect amino acid is substituted in the polypeptide chain. Cystathionine beta-synthase (CBS) deficiency is an example of an IEM that causes large elevations of blood total homocysteine levels, resulting in phenotypes in several tissues. Current treatment strategies involve dietary restriction and vitamin therapy, but these are only partially effective and do not work in all patients. Over 85% of the described mutations in CBS-deficient patients are missense mutations in which the mutant protein fails to fold into an active conformation. The ability of CBS to achieve an active conformation is affected by a variety of intracellular protein networks including the chaperone system and the ubiquitin/proteasome system, collectively referred to as the proteostasis network. Proteostasis modulators are drugs that perturb various aspects of these networks. In this article, we will review the evidence that modulation of the intracellular protein folding environment can be used as a potential therapeutic strategy to treat CBS deficiency and discuss the pros and cons of such a strategy.

摘要

先天性代谢缺陷(IEM)包括一大类隐性遗传疾病,涉及细胞代谢紊乱,这些疾病往往是由多肽链中单个错误氨基酸取代引起的错义突变引起的。胱硫醚β-合酶(CBS)缺乏是一种导致血液总同型半胱氨酸水平大幅升高的 IEM ,导致多种组织出现表型。目前的治疗策略包括饮食限制和维生素治疗,但这些方法仅部分有效,并非对所有患者都有效。在 CBS 缺乏症患者中,超过 85%的描述性突变是错义突变,其中突变蛋白无法折叠成活性构象。CBS 形成活性构象的能力受到各种细胞内蛋白质网络的影响,包括伴侣蛋白系统和泛素/蛋白酶体系统,统称为蛋白质稳态网络。蛋白质稳态调节剂是一种能够扰乱这些网络各个方面的药物。在本文中,我们将回顾调节细胞内蛋白质折叠环境可作为治疗 CBS 缺乏症的潜在治疗策略的证据,并讨论这种策略的优缺点。